Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03076775 · ClinicalTrials.gov registry record · NA
Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study
A NA study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- NA
- Development phase
- 86
- Enrollment target
NCT03076775 is a NA study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 86 participants.
The verdict
NCT03076775, a NA study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- NA
- Development phase
- 86 participants
- Enrollment target
Study Summary
Annually in the U.S 300,000 neonates are born late preterm, defined as 34 weeks 0 days - 36 weeks 6 days. The Antenatal Late Preterm Steroids (ALPS) Trial demonstrated that maternal treatment with betamethasone in the late preterm period significantly reduces neonatal respiratory complications, but also increases neonatal hypoglycemia, compared to placebo. This research study will attempt to answer the following primary question: Does a management protocol aimed at maintaining maternal euglycemia after ALPS decrease fetal hyperinsulinemia, compared to usual antepartum care?
Interventions
- OTHER Maternal glycemic control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2017-06-08 |
| Est. Completion | 2021-11-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03076775
The ClinicalTrials.gov registry entry for NCT03076775 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Maternal glycemic control is the first listed.
NCT03076775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03076775 about?
NCT03076775 is a clinical study titled "Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study". Annually in the U.S 300,000 neonates are born late preterm, defined as 34 weeks 0 days - 36 weeks 6 days. The Antenatal Late Preterm Steroids (ALPS) Trial demonstrated that maternal treatment with betamethasone in the late preterm period significantly reduces neonatal respiratory complications, but ...
What is the current status of trial NCT03076775?
This trial is currently completed. It is a NA study. The enrollment target is 86 participants. The study started on 2017-06-08. Estimated completion is 2021-11-19.
What interventions are being tested in trial NCT03076775?
The interventions under investigation include: Maternal glycemic control (OTHER).
Who is sponsoring clinical trial NCT03076775?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.